TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33692190
Drug: Smart agent
Normalized name: benzalkonium chloride Topical Foam [Smart San]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smart agent (SA) system
Study: 33781141
Drug: BMS‐986020 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐986020 600 mg once daily (QD)
Study: 33781141
Drug: BMS‐986020 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐986020 600 mg twice daily (BID)
Study: 32106642
Drug: Nebulized heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized heparin (25,000 IU) and salbutamol (5 mg) every 6 hours
Study: 32106642
Drug: Salbutamol only
Normalized name: Salbutamol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol only (5 mg)
Study: 36471692
Drug: Remimazolam tosylate
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam tosylate plus low-dose propofol (Group RP)
Study: 34916266
Drug: Low-dose dexamethasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dexamethasone (6 mg once daily for 10 days)
Study: 34916266
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone (20 mg once daily for 5 days, followed by 10 mg once daily for an additional 5 days)
Study: 32019723
Drug: MLR-1023 100-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLR-1023 100-mg once-daily (qd)
Study: 32019723
Drug: MLR-1023 100-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLR-1023 100-mg twice-daily (bid)
Study: 32019723
Drug: MLR-1023 200-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLR-1023 200-mg once-daily (qd)
Study: 32019723
Drug: MLR-1023 200-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLR-1023 200-mg twice-daily (bid)
Study: 32931400
Drug: Olanzapine 0.14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 0.14 mg/kg/day (maximum 10 mg) during chemotherapy and 3 days postchemotherapy
Study: 33508499
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS treatment (5-Hz) for 2 weeks
Study: 33508499
Drug: Active rTMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rTMS treatment (5-Hz) for 6 months (open-label maintenance phase)
Study: 33508499
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment for 2 weeks
Study: 36153583
Drug: Atorvastatin (n=27)
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin (n=27)
Study: 35638203
Drug: Three PRP
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three PRP injections
Study: 35638203
Drug: One PRP
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One PRP injection followed by two placebo injections
Study: 35638203
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections (Normal Saline)
Study: 35638203
Drug: Single or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple PRP injections
Study: 35638203
Drug: Single PRP
Normalized name: HEMOPHILUS B PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single PRP injection
Study: 35638203
Drug: Multiple PRP
Normalized name: HEMOPHILUS B PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple PRP injections
Study: 32856285
Drug: Oral sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sildenafil (0.5 mg/kg every 6 hours to a target maintenance dose of 2 mg/kg every 6 hours)
Study: 32856285
Drug: Intravenous milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous milrinone (0.5 μg/kg/min as a continuous infusion)
Study: 32856285
Drug: Oral sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sildenafil and intravenous milrinone (dual therapy)
Study: 35360742
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TEAS and palonosetron
Study: 35164840
Drug: Intranasal dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal dexamethasone
Study: 35164840
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (intranasal and intravenous dexamethasone)
Study: 32591274
Drug: L-PRF membranes
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-PRF membranes
Study: 32366244
Drug: Lanreotide autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide autogel 60/90/120 mg (monthly deep subcutaneous injection)
Study: 32366244
Drug: Lanreotide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide 40 mg PR (intramuscular injection every 7, 10, or 14 days)
Study: 32366244
Drug: Lanreotide 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide 40 mg PR
Study: 32452085
Drug: Patiromer (8.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer (8.4 g once daily)
Study: 34428179
Drug: Fractionated laser
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated laser resurfacing (FLR) treatment on one lower arm
Study: 33905494
Drug: Oral doxycycline
Normalized name: doxycycline Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxycycline 200 mg twice daily for 10 days and prednisolone 60 mg once daily for 5 days, then tapered over 5 days
Study: 33905494
Drug: Oral doxycycline
Normalized name: doxycycline Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doxycycline (historical control)
Study: 32348882
Drug: Glucose syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose syrup (0.5-3 mL)
Study: 32348882
Drug: Glucose syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose syrup
Study: 33720089
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy with oral nucleoside analogue (entecavir or lamivudine) combined with subcutaneous peginterferon alfa-2a from week 8 for 56 weeks
Study: 32171765
Drug: Intrastromal injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRACORONAL, DENTAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrastromal injection of voriconazole
Study: 32171765
Drug: Topical therapy
Normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapy alone
Study: 35567757
Drug: Low-dose bicyclol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose bicyclol (25 mg TID)
Study: 35567757
Drug: High-dose bicyclol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose bicyclol (50 mg TID)
Study: 36247895
Drug: Group g
Normalized name: Prostaglandin group G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group g (0.08 mCi/kg/180 s) for PET imaging
Study: 35283082
Drug: Hormonal contraception
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormonal contraception (various methods including implants, IUDs, combined pills, progestin-only pills, injectables, ring, patch)
Study: 33517804
Drug: L-Carnitine
Normalized name: L-Carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-Carnitine
Study: 34366380
Drug: Foslevodopa/foscarbidopa administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foslevodopa/foscarbidopa administered via abdominal SC infusion over 72 hours
Study: 34366380
Drug: Foslevodopa/foscarbidopa infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foslevodopa/foscarbidopa infusion
Study: 33333055
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CA19-9 with LRG1 and TIMP1
Study: 32697889
Drug: SCThrive intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCThrive intervention (six weekly group sessions, in-person booster session, companion app usage)
Study: 32697889
Drug: SCHealthEd intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SCHealthEd intervention (six weekly phone calls on SCD-related and general health education topics)
Study: 35753247
Drug: 100% pure
Normalized name: 100% Pure Australian Tea Tree Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% pure oxygen inhalation (hyperoxic CHRS testing)
Study: 32699919
Drug: ST/gracilis (ST/G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST/gracilis (ST/G) graft with femoral pin transfixation and tibial bioscrew fixation
Study: 32699919
Drug: ST/gracilis (ST/G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST/gracilis (ST/G) graft
Study: 34852266
Drug: Minimal fresh
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal fresh gas flow (FGF) sevoflurane anesthesia (0.5 L.min−1)
Study: 34852266
Drug: High fresh
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fresh gas flow (FGF) sevoflurane anesthesia (2.0 L.min−1)
Study: 33208708
Drug: Venlafaxine (VF,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (VF, 150-375 mg/d)
Study: 33109394
Drug: Standard smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard smoking cessation treatment + enhanced cue‐based treatment (interactive texting and cue management counseling)
Study: 33109394
Drug: Standard smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard smoking cessation treatment + enhanced cue‐based treatment
Study: 32062371
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose hydrocortisone (LDH 10 mg)
Study: 36224692
Drug: Norepinephrine 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine 0.025 μg/(kg·min)
Study: 36224692
Drug: Norepinephrine 0.050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine 0.050 μg/(kg·min)
Study: 36224692
Drug: Norepinephrine 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine 0.075 μg/(kg·min)
Study: 36224692
Drug: Norepinephrine 0.100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine 0.100 μg/(kg·min)
Study: 36224692
Drug: Norepinephrine 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine 0.125 μg/(kg·min)
Study: 32584367
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab emtansine (T-DM1) plus capecitabine (at phase 1 MTD of 700 mg/m2)
Study: 34216466
Drug: Standard subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard subcutaneous infiltration of dilute lidocaine solution
Study: 32354366
Drug: Randomization to
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization to low dose aspirin prior to pregnancy
Study: 34372746
Drug: New prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: New prolonged-release leuprorelin acetate microspheres for injection (3.75 mg)
Study: 34372746
Drug: Enantone® (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enantone® (3.75 mg)
Study: 33052400
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intravenous tropisetron before anesthesia induction
Study: 32669121
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment using closed reduction and plaster immobilisation
Study: 35690316
Drug: Phosphodiesterase‐5 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphodiesterase‐5 inhibitors (PDE‐5i)
Study: 33506054
Drug: Glucocorticoid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid treatment for 2 weeks
Study: 32857315
Drug: Ozanimod 0.46
Normalized name: ozanimod 0.46 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod 0.46 mg (group A, n = 20)
Study: 32857315
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg twice daily for 17 days + ozanimod 0.46 mg on day 4 (group B, n = 20)
Study: 32857315
Drug: Ozanimod 0.92
Normalized name: ozanimod 0.92 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod 0.92 mg (group C, n = 20)
Study: 32857315
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg once daily for 17 days + ozanimod 0.92 mg on day 4 (group D, n = 20)
Study: 32857315
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg once daily for 21 days + ozanimod 0.92 mg on day 8 (group E, n = 20)
Study: 32668845
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for childhood cancer, details on dosage and duration not available.
Study: 33055544
Drug: Gum chewing
Normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum chewing (mint-flavored sugar-free gum) for 20 minutes every 2 hours until colonoscopy after consuming 2 L of polyethylene glycol solution
Study: 33055544
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol solution (control group)
Study: 34779392
Drug: Transdermal contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal contraceptive patch with newly sourced adhesive component at end of shelf life (EOSL)
Study: 34779392
Drug: EVRA patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVRA patch at beginning of shelf life (BOSL)
Study: 34309426
Drug: 0.18-mg fluocinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.18-mg fluocinolone acetonide insert
Study: 35139273
Drug: Cemiplimab (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemiplimab (350 mg every 3 weeks)
Study: 35139273
Drug: Chemotherapy (investigator's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (investigator's choice of single-agent chemotherapy)
Study: 36807215
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no laser treatment).
Study: 35915917
Drug: Benson's Relaxation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benson's Relaxation, performed twice a day for 10 minutes for 8 weeks after a training session
Study: 34415011
Drug: acceptance-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: acceptance-based treatment (ABT)
Study: 34375712
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (MT) with imbedded 10 Hz binaural beats combined with standard treatment
Study: 35331191
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT)-based self-help IMI
Study: 34001070
Drug: Feeding volume
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feeding volume < 80 mL/kg/d at the end of the 4th week after birth
Study: 34001070
Drug: Prolonged (>
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged (> 2 weeks) diuretics application
Study: 35060026
Drug: Enhanced coagulation-flocculant
Normalized name: Coagulation factor XIa
DrugBank: Coagulation factor XIa (DB15420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced coagulation-flocculant process incorporating magnetic powder; 28.42 mg/L coagulant, 623 mg/L magnetic powder, 0.18 mg/L flocculant
Study: 33289602
Drug: Sodium Hyaluronate/Chondroitin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Hyaluronate/Chondroitin Sulfate Preservative-free Ophthalmic Solution (SH/CS‐PF)
Study: 36199177
Drug: Fenugreek seed
Normalized name: FENUGREEK SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek seed extract (5 cc) for 4 months
Study: 34116144
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan (SG) 10 mg/kg intravenously on days 1 and 8, every 21 days
Study: 36427229
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (HBO)
Study: 33140886
Drug: Opioid receptor
Normalized name: Opioid receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid receptor antagonist naltrexone
Study: 35441795
Drug: Tumescent solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumescent solution with ropivacaine
Study: 35441795
Drug: Tumescent solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumescent solution without ropivacaine
Study: 35441795
Drug: Tumescent solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumescent solution with/without ropivacaine (inter-group comparison)
Study: 33780271
Drug: 6-session solution-oriented
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-session solution-oriented goal-setting program
Study: 32690072
Drug: Olanzapine (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (starting dose 5 mg daily, maximum 20 mg daily)
Study: 33588590
Drug: Intravenous Thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Thrombolysis (IVT)
Study: 36163903
Drug: Ponatinib 45
Normalized name: PONATinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib 45 mg QD (PACE)
Study: 36163903
Drug: Ponatinib 45
Normalized name: PONATinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib 45 mg QD (OPTIC)
Study: 32524584
Drug: Early relapse
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early relapse after high-dose melphalan autologous stem cell transplant
Study: 32524584
Drug: Later relapsing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Later relapsing patients after high-dose melphalan autologous stem cell transplant
Study: 33380392
Drug: Intravenous analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous analgesia (GA)
Study: 33858190
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin plus standard chemotherapy (GO + SC)
Study: 33858190
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy alone (SC)
Study: 33786671
Drug: Experimental solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental solution (methylene blue dye with cetrimide) and aPDT
Study: 33116410
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of valsartan 80 mg capsules under fasting conditions
Study: 33116410
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of valsartan 80 mg capsules under fed conditions
Study: 33116410
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of valsartan 80 mg capsules
Study: 36165675
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day prednisolone for 2 years
Study: 37164774
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (ICT) followed by curative chemo-radiotherapy (CTRT) or surgery and adjuvant (chemo)RT
Study: 33620447
Drug: Internet-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based treatment via smartphone application
Study: 34780107
Drug: Longstanding active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longstanding active exercise therapy (52 weeks)
Study: 35098177
Drug: ARCoV mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARCoV mRNA vaccine (5 µg, 10 µg, 15 µg, 20 µg, 25 µg)
Study: 35098177
Drug: ARCoV mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARCoV mRNA vaccine
Study: 35098177
Drug: ARCoV mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARCoV mRNA vaccine (15 µg)
Study: 34622504
Drug: 7-day vonoprazan-based
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 7-day vonoprazan-based triple therapy (7-VAC): vonoprazan 20 mg bid. pc., amoxicillin 1000 mg bid. pc., clarithromycin 500 mg bid. pc.
Study: 34622504
Drug: 14-day omeprazole-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day omeprazole-based triple therapy (14-OAC): omeprazole 20 mg bid. ac., amoxicillin 1000 mg bid. pc., clarithromycin 500 mg bid. pc.
Study: 34866250
Drug: Short Implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short Implants (SI)
Study: 34866250
Drug: Standard Length
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Length Implants (SLI) with MSFA
Study: 32173228
Drug: Health education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health education intervention consisting of oral presentation and distribution of fliers for 30 minutes.
Study: 34154321
Drug: Neridronate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neridronate (25 mg i.m./month)
Study: 35733086
Drug: Lidocaine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (4 ml of 2% lidocaine in the outer cuff)
Study: 35733086
Drug: Remifentanil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (2 ng/ml maintained until extubation)
Study: 33302570
Drug: 25‐hydroxyvitamin D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25‐hydroxyvitamin D3 (25OHD) 10 µg per day for 16 weeks
Study: 33653118
Drug: Ezogabine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezogabine (900 mg/day; N=21)
Study: 33338441
Drug: SARS-CoV-2 antibody
Normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 antibody seropositivity in the general population
Study: 33338441
Drug: SARS-CoV-2 antibody
Normalized name: SARS-CoV-2 antibody-based IVIG
DrugBank: Anti-SARS-CoV-2 immunoglobulin (DB16360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 antibody seropositivity in the high-risk population